The CTOS 2025 Annual Meeting brought together leading experts in sarcoma research and clinical care, reaffirming its role as the premier global forum dedicated to improving outcomes for patients with bone and soft-tissue tumors. Held from November 5 to 8, the meeting showcased cutting-edge science, multidisciplinary collaboration, and translational innovation.
Hosted by the Connective Tissue Oncology Society (CTOS), the congress continued its tradition of uniting oncologists, surgeons, pathologists, radiation oncologists, researchers, and patient advocates from across the world. As one of the most influential gatherings in the sarcoma community, CTOS 2025 provided a platform to discuss new data, clinical progress, and future directions in rare tumor management.
The scientific program highlighted major advancements in sarcoma biology, novel immunotherapeutic strategies, targeted therapy development, limb-sparing surgical techniques, and radiotherapy innovations. Plenary sessions, oral abstracts, and poster discussions presented breakthroughs across the spectrum of care, from molecular characterization and precision medicine to survivorship and quality-of-life research.
20 Posts Not to Miss from CTOS 2025
“The countdown is over! CTOS2025 just started with the Foundation Science of Sarcoma symposium and a fantastic keynote by Kathryn Lemberg on metabolism as a target for sarcoma therapies. Stay tuned for more updates on great science that will be presented over the next 4 days!”
“CTOS2025 30th Anniversary kick-off! President Silvia Stacchia
start the opening!”
“Surveillance study from Australia in multiorgan cancer-prone syndromes 268 participants from 2013-2025. New cancer detection rates per year of following up: TP53 1 in 13 people (7.6%); RB1 1 in 20 (5.1%), NF1 1 in 14 (7.1%). No negative psychological impact of study.”
“ctosociety has helped bridge friendships and collaborations between the U.S. and colleagues around the world. Even with differing opinions, it gave us a space to discuss challenging cases, something we should truly appreciate at conferences like this! ~Prof. Ian Judson”
“What a distinguished panel of Sarcoma icons giving their perspective the history and evolution of MDT care CTOS2025”
“AdAPT-001 (oncolytic adenovirus + TGF-β trap) + checkpoint inhibitor shows durable responses in refractory angiosarcoma with mPFS > 8 mo and mild TRAEs. Presented by Vinod Ravi.”
“Celebrating the 30th anniversary of CTOS with the President’s message, highlighting the three core traits of our society: global collaboration, friendship, and a shared commitment to progress!”
“Robin Lewis Jones,The Royal Marsden Cancer Charity presenting ChonDRAgon PhII registrational study of Ozekibart in conventional chondrosarcoma CTOS2025 – No approved systemic therapies – mPFS 5.5 mo, with 21.7% w/o prog 12 mo – Activity in both IDH-WT & mut – TRAE incl ~13% fatigue, ~6% hepatitis.”
Myrsini Ioakeim-Ioannidou, MD:
“Honored to present our skull base chondrosarcoma dose-escalation trial at CTOS2025 – especially meaningful as chondrosarcoma was named Sarcoma of the Year. Grateful to receive the CTOS Young Investigator Award for this work. Proud to represent Mass General Brigham and our incredible sarcoma team.”
“Great time at CTOS2025 connecting with sarcoma colleagues across the globe and spending time with the UT Southwestern Sarcoma Team outside of the office!”
“Proud and smart Chirurgia dei Sarcomi INT delegates at CTOS2025 1 Chair-Mentor-Lead-etc 1 surgeon and that’s all 1 ctosociety
scient program committee member 1 Italian Sarcoma Group
Fellow 1 UofT Surgical Oncology CGSO Fellow 1 CRC Resar admin 1 RN (very proud of you!)”
“Honored to share our Phase 1/2 data from MD Anderson at CTOS2025 today • DR5 agonists demonstrated improved PFS compared with other therapies • Stable disease with any tumor reduction (SD-ATR) was associated with improved PFS and OS and may be a meaningful surrogate endpoint Grateful to our patients and the Sarcoma & Phase 1 teams.”
“Grateful for an amazing CTOS2025. Thrilled to share our work through both an oral and poster presentation!”
“Honoured to present my poster on maintenance with dacarbazine in advanced LMS pts and to attend a wonderful presentation by Chiara Fabbroni about our case series of advanced PEComa pts treated with mTORi + Al. CTOS2025 day 2 has been wrapped up.”
“Super cool large language model AI work looking at sarcoma clinical data. CTOS2025”
“Last day of CTOS2025 Thanks to Gina Z. D’Amato, MD.
for being an amazing mentor AND for planning such a productive conference!”
“ctosociety ctos2025 did not disappoint. Great to hear how our colleagues around the world are advancing #sarcoma science and treatment.”
“Desmoid has a sustained impact on pts lives at 10yr of disease only half remain at full time job ONLY 17% received counseling by reproductive specialists Desmoid pts are often excluded from supportive programs reserved for cancer survivors.”
“StandingCommittees meeting of ctosociety at CTOS2025. Dedicated members helping to shape our society and cater for our members. We are looking for more members to join! Find out more at https://ctos.org/About/Committees.aspx and contact committee chairs for more info!”
“Last day ctos2025 presented NRG-DT 001 NRG Oncology! mdm2 inhibition with RT in WT p53 STS. Must give another shout out to BVT- Brian Van Tine who was the best medical co-chair.”
More posts about CTOS 2025 are available on OncoDaily.
Written by Nare Hovhannisyan, MD